A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma

To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 patients treated with venetoclax monotherapy (n = 50, 62%) or in combination with a Bruton tyrosine kinase inhibitor (BTKi) (n = 16, 20%), an anti-CD20 monoclonal antibody (n = 11, 14%), or ot...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawalha, Yazeed, Goyal, Subir, Switchenko, Jeffrey M., Romancik, Jason T., Kamdar, Manali, Greenwell, I. Brian, Hess, Brian T., Isaac, Krista M., Portell, Craig A., Mejia Garcia, Alex, Goldsmith, Scott, Grover, Natalie S., Riedell, Peter A., Karmali, Reem, Burkart, Madelyn, Buege, Michael, Akhtar, Othman, Torka, Pallawi, Kumar, Anita, Hill, Brian T., Kahl, Brad S., Cohen, Jonathon B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320213/
https://www.ncbi.nlm.nih.gov/pubmed/36809796
http://dx.doi.org/10.1182/bloodadvances.2022008916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320213/
https://www.ncbi.nlm.nih.gov/pubmed/36809796
http://dx.doi.org/10.1182/bloodadvances.2022008916

Ejemplares similares